Active	Status	Sponsor type	Region	Phase	Filter
4 Active 5 Inactive 9 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   - « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Aemcolo (rifamycin SV MMX) / Cosmo Pharma, RedHill, Dr Falk
NCT04501380: Efficacy of AEMCOLO (Rifamycin SV MMX) in the Treatment of Small Intestinal Bacterial Overgrowth (SIBO)	Enrolling by invitation	2	30	US	AEMCOLO (Rifamycin SV MMX)	Bradley Connor	Small Intestinal Bacterial Overgrowth, Gastrointestinal Disease, Gastrointestinal Infection	12/22	12/22
RIVET, NCT04082780: Rifamycin in Minimal Hepatic Encephalopathy	Completed	2	30	US	Rifamycin SV MMX, Aemcolo, Placebo	Hunter Holmes Mcguire Veteran Affairs Medical Center	Hepatic Encephalopathy, Cirrhosis, Liver	04/23	04/23
NCT04027894: Study to Evaluate Safety and Efficacy of Rifamycin SV MMX in Treating Traveler's Diarrhea in Children Age 12 to 17 Years	Not yet recruiting	2	142	NA	Rifamycin SV MMX, Rifamycin, Placebo to Rifamycin SV-MMX, Placebo	RedHill Biopharma Limited	Traveler's Diarrhea	01/25	12/25
NCT04026984: Evaluate Safety and Efficacy of Rifamycin SV MMX in the Treatment of Traveler's Diarrhea in Children Age 6 to 11 Years	Not yet recruiting	2	142	NA	Rifamycin SV-MMX, Rifamycin, Placebo	RedHill Biopharma Limited	Traveler's Diarrhea	06/25	12/25

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Aemcolo (rifamycin SV MMX) / Cosmo Pharma, RedHill, Dr Falk
NCT04501380: Efficacy of AEMCOLO (Rifamycin SV MMX) in the Treatment of Small Intestinal Bacterial Overgrowth (SIBO)	Enrolling by invitation	2	30	US	AEMCOLO (Rifamycin SV MMX)	Bradley Connor	Small Intestinal Bacterial Overgrowth, Gastrointestinal Disease, Gastrointestinal Infection	12/22	12/22
RIVET, NCT04082780: Rifamycin in Minimal Hepatic Encephalopathy	Completed	2	30	US	Rifamycin SV MMX, Aemcolo, Placebo	Hunter Holmes Mcguire Veteran Affairs Medical Center	Hepatic Encephalopathy, Cirrhosis, Liver	04/23	04/23
NCT04027894: Study to Evaluate Safety and Efficacy of Rifamycin SV MMX in Treating Traveler's Diarrhea in Children Age 12 to 17 Years	Not yet recruiting	2	142	NA	Rifamycin SV MMX, Rifamycin, Placebo to Rifamycin SV-MMX, Placebo	RedHill Biopharma Limited	Traveler's Diarrhea	01/25	12/25
NCT04026984: Evaluate Safety and Efficacy of Rifamycin SV MMX in the Treatment of Traveler's Diarrhea in Children Age 6 to 11 Years	Not yet recruiting	2	142	NA	Rifamycin SV-MMX, Rifamycin, Placebo	RedHill Biopharma Limited	Traveler's Diarrhea	06/25	12/25